Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCurrys Regulatory News (CURY)

Share Price Information for Currys (CURY)

Share Price is delayed by 15 minutes
Get Live Data
152.60    -0.40 (-0.26%)
Bid:
152.90
Ask:
153.20
Spread: 0.30 (0.196%)
Market Cap: £1.58b
CURY Live PriceLast checked at - London Stock Exchange

Intraday Currys Share Chart

Director/PDMR Shareholding

28 Jul 2023 10:58

RNS Number : 5718H
Currys PLC
28 July 2023
 

28 July 2023

 

NOTIFICATION OF GRANT OF SHARE AWARDS

 

Currys plc (the "Company")

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMR") and persons closely associated with them in accordance with the Market Abuse Regulations.

Awards under the Currys plc Long Term Incentive Plan 2016

On 28 July 2023, the following awards (the "Awards") over ordinary shares of 0.1 pence in the Company ("Ordinary Shares") were granted under the Currys plc Long Term Incentive Plan 2016 ("LTIP"):

Name of Director / PDMR

Base Salary for Award (£)

Award Reference Value (£)

No. of Ordinary Shares under Award

Vesting Date

Exercise Price

Alex Baldock

906,400

1,926,100

3,642,742

28 July 2026

Nil

Bruce Marsh

487,400

1,035,725

1,958,817

28 July 2026

Nil

Due to current market volatility, the share price used to determine the number of shares making up each Award (each a nil cost option) was calculated using the average mid-market price at the close of business since the announcement of the Company results on 6 July 2023 to the business day prior to grant, being 27 July 2023 (£0.52875). This is consistent with the approach used last year.

The number of Ordinary Shares stated above is the maximum number that could vest to each PDMR upon full satisfaction of the performance conditions attaching to the Awards.

The Awards will ordinarily vest and become exercisable on 28 July 2026 (the "Vesting Date"), subject to each PDMR's continued service with the Company and the extent to which the performance conditions applicable to the Awards are achieved. In the case of the awards granted to Alex Baldock and Bruce Marsh, any Ordinary Shares which vest will be subject to an additional two-year holding period (on a net of tax basis) from the Vesting Date.

Taking into account the feedback received from shareholders that EPS is a key measure for them, the Remuneration Committee has decided to introduce this as an element alongside existing free cash flow and relative TSR. The Committee took the opportunity to review the vesting schedules and decided to make these all consistent the existing TSR metric, with 25% of the relevant portion of the award vesting for a Threshold level of performance and straight line vesting up to 100% for a Stretch level of performance. In considering the calibration of targets, the Committee considered both internal business expectations and external analyst forecasts and is comfortable that these represent an appropriate degree of stretch and value creation for shareholders.

 

The performance conditions applicable to the Awards are set out as follows:

1) 30% Relative Total Shareholder Return ("TSR")

30% of the Award is subject to the achievement of a relative TSR performance condition, measured against the companies ranked in the FTSE 250 at the start of the performance period. The starting point for measurement will be 30 April 2023 and the closing point will be the final day of the 2025/2026 Financial Year, with one month averaging periods up to the beginning and end of the performance period. 25% of this portion of the Award will vest for achievement of median TSR versus the comparator group, with maximum vesting at upper quartile or above and straight-line vesting between these two points.

2) 40% Cumulative Free Cash Flow

40% of the Award is subject to the achievement of a performance condition measuring the Company's cumulative free cash flow over the three-year period starting on 30 April 2023 and ending on the final day of the 2025/2026 Financial Year. 25% of this portion of the Awards will vest if cumulative free cash flow over the three-year period is £226m, rising to 100% of this portion of the Award vesting if cumulative free cash flow over the three-year period is £306m or higher, and straight-line vesting between these points.

3) 30% Cumulative EPS

30% of the Award is subject to the achievement of a performance condition measuring the Company's cumulative adjusted basic EPS over the three-year period starting on 30 April 2023 and ending on the final day of the 2025/2026 Financial Year. 25% of this portion of the Award will vest if cumulative adjusted basic EPS over the three-year period is 24.4p, rising to 100% of this portion of the Award vesting if cumulative adjusted basic EPS over the three-year period is 33.0p or higher, and straight-line vesting between these points.

Calculation of the number of Shares subject to the Awards

The Remuneration Committee is mindful of aligning with shareholder experience in the context of recent market volatility and the number of shares that would be awarded as a result of the current lower share price. The Committee has therefore decided to apply a 15% scale back to the normal award level, resulting in awards to the Executive Directors of 212.5% of salary compared to the normal award level of 250% awarded in 2022. The Committee will also consider the formulaic outcome at the time of vesting to ensure that this is aligned with the holistic performance achieved and the broader stakeholder experience. The Committee may use discretion to adjust the outcome downwards if appropriate in the specific circumstances.

This announcement is made in accordance with the requirements of Market Abuse Regulation Article 19. 

As at the date of this announcement, the Company has 1,133,494,651 Ordinary Shares in issue.

 

Details of the full notifications received by the Company are set out below.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Alex Baldock

2

Reason for Notification

a)

Position/status

Group Chief Executive

b)

Initial notification/Amendment

Initial Announcement

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Currys plc

b)

LEI

2138001E12GWLLDQQF16

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Ordinary Shares of 0.1 pence each in Currys plc

Identification code

GB00B4Y7R145

b)

Nature of the transaction

Grant of a nil cost option award under the Currys plc Long Term Incentive Plan. The award will ordinarily become exercisable three years from the date of grant, subject to the grantee's continued service and the extent to which the performance conditions applicable to the award have been met, and then may be exercised for a period of ten years from the date of grant.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

3,642,742

d)

Aggregated information

- Aggregated volume

- Price

Not applicable - single transaction

e)

Date of the transaction

28 July 2023

f)

Place of the transaction

Outside a trading venue

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bruce Marsh

2

Reason for Notification

a)

Position/status

Group Chief Financial Officer

b)

Initial notification/Amendment

Initial Announcement

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Currys plc

b)

LEI

2138001E12GWLLDQQF16

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Ordinary Shares of 0.1 pence each in Currys plc

Identification code

GB00B4Y7R145

b)

Nature of the transaction

Grant of a nil cost option award under the Currys plc Long Term Incentive Plan. The award will ordinarily become exercisable three years from the date of grant, subject to the grantee's continued service and the extent to which the performance conditions applicable to the award have been met, and then may be exercised for a period of ten years from the date of grant.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

1,958,817

d)

Aggregated information

- Aggregated volume

- Price

Not applicable - single transaction

e)

Date of the transaction

28 July 2023

f)

Place of the transaction

Outside a trading venue

 

 

Enquiries:

 

Sarah Thomas Deputy Company Secretary +44 (0)7401 373 188

 

Dan Homan Head of Investor Relations +44 (0)7401 400 442

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGCGDRLUDDGXI
Date   Source Headline
18th Jan 20247:00 amRNSStrengthening performance in a tough environment
2nd Jan 202412:52 pmRNSTotal Voting Rights
21st Dec 20232:54 pmRNSHolding(s) in Company
21st Dec 202310:40 amRNSHolding(s) in Company
20th Dec 20239:54 amRNSHolding(s) in Company
14th Dec 20235:24 pmRNSHolding(s) in Company
14th Dec 20237:00 amRNSSolid performance in a tough environment
1st Dec 20239:06 amRNSTotal Voting Rights
21st Nov 202312:01 pmRNSResult of Meeting
3rd Nov 202312:25 pmRNSShareholder Circular and Notice of General Meeting
3rd Nov 20237:05 amRNSProposed Disposal of Kotsovolos
1st Nov 20239:41 amRNSTotal Voting Rights
10th Oct 20237:27 amRNSUpdate on Strategic Review of Kotsovolos
6th Oct 20233:16 pmRNSHolding(s) in Company
2nd Oct 202311:26 amRNSTotal Voting Rights
28th Sep 202310:55 amRNSHolding(s) in Company
20th Sep 202310:35 amRNSDirector/PDMR Shareholding
19th Sep 202310:35 amRNSHolding(s) in Company
7th Sep 20231:51 pmRNSResult of AGM
7th Sep 20237:00 amRNSAGM Trading Statement
1st Sep 20239:09 amRNSTotal Voting Rights
22nd Aug 20233:58 pmRNSDirector/PDMR Shareholding
17th Aug 202312:40 pmRNSDirector/PDMR Shareholding
4th Aug 20239:44 amRNSDirector/PDMR Shareholding
3rd Aug 202312:54 pmRNSAnnual Financial Report
3rd Aug 20239:25 amRNSDirector/PDMR Shareholding
1st Aug 202311:09 amRNSTotal Voting Rights
28th Jul 202310:58 amRNSDirector/PDMR Shareholding
13th Jul 20238:30 amRNSHolding(s) in Company
12th Jul 20234:14 pmRNSHolding(s) in Company
11th Jul 20239:42 amRNSHolding(s) in Company
10th Jul 20232:59 pmRNSDirector/PDMR Shareholding
7th Jul 202310:36 amRNSDirector/PDMR Shareholding
6th Jul 20231:26 pmRNSDirector/PDMR Shareholding
6th Jul 20237:00 amRNSStrengthening UK&I offset by poor Nordics
3rd Jul 20239:55 amRNSTotal Voting Rights
26th Jun 202312:14 pmRNSHolding(s) in Company
23rd Jun 20234:23 pmRNSHolding(s) in Company
22nd Jun 20239:22 amRNSHolding(s) in Company
19th Jun 20235:20 pmRNSHolding(s) in Company
19th Jun 20234:38 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSStrategic Review of Kotsovolos
2nd Jun 202310:37 amRNSDirectorate Change
1st Jun 20239:33 amRNSTotal Voting Rights
24th May 20238:37 amRNSResponse to ESA announcement
15th May 20237:00 amRNSTrading Statement
3rd May 20235:21 pmRNSHolding(s) in Company
2nd May 202311:43 amRNSTotal Voting Rights
11th Apr 20235:53 pmRNSHolding(s) in Company
5th Apr 202310:30 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.